Abcellera Biologics Inc represents a commitment to cutting-edge biotechnology and scientific innovation. The company values include excellence, integrity, and collaboration. Abcellera embraces a customer-centric approach, striving to deliver solutions that advance health and well-being. Their corporate philosophy emphasizes the importance of transformative research, driving breakthroughs in drug discovery and development. With a focus on antibody therapeutics, Abcellera aims to push boundaries and revolutionize the treatment landscape for various diseases. By combining technology, data analysis, and the expertise of their diverse team, Abcellera Biologics Inc strives to make a lasting impact in the field of biopharmaceuticals.

Abcellera Biologics Inc is primarily present in Canada and the United States.

Abcellera Biologics Inc has achieved significant milestones within the biotechnology industry. The company successfully went public in December 2020, raising substantial funds to support its research and development efforts. Abcellera is renowned for its revolutionary antibody discovery platform, which played a crucial role in the development of therapies for various diseases, including COVID-19. The company formed essential partnerships with leading pharmaceutical firms, such as Eli Lilly, to expedite the production and distribution of monoclonal antibody treatments. Abcellera's groundbreaking AI-driven approach and its contributions to advancing biotherapeutics have positioned it as a key player in the field.

Abcellera Biologics Inc is a leading biotechnology company specializing in antibody discovery. Founded in 2012, Abcellera has emerged as a key player in the field of therapeutic antibody development. The company utilizes a powerful technology platform that combines high-throughput single-cell analysis, microfluidics, and genomics to rapidly identify and develop antibodies for various diseases, including infectious diseases and cancer. Abcellera has formed strategic partnerships with renowned pharmaceutical companies and research institutions, enabling them to accelerate the discovery and development of new therapies. With its innovative approach and cutting-edge technology, Abcellera Biologics Inc continues to make significant contributions to the field of biotechnology and healthcare.

The main competitors of Abcellera Biologics Inc in the market are companies such as Regeneron Pharmaceuticals, Eli Lilly and Company, and Gilead Sciences.

Abcellera Biologics Inc is primarily active in the biotechnology industry.

The business model of Abcellera Biologics Inc revolves around advancing the discovery of new antibody therapies through their innovative platform. Abcellera utilizes advanced technologies, including artificial intelligence and high-throughput single-cell screening, to identify and analyze antibodies from natural immune systems. This enables them to rapidly discover high-quality antibody candidates for various diseases, including infectious diseases and cancer. Abcellera then partners with biotechnology and pharmaceutical companies to co-develop these antibodies into potential therapies. By leveraging their robust technology and collaborative approach, Abcellera aims to accelerate the development of novel antibody-based treatments for improved patient outcomes.

Abcellera Biologics KGV ir -4,58.

Abcellera Biologics KUV ir 18,38.

AlleAktien kvalitātes vērtējums Abcellera Biologics ir 2/10.

gaidāmā Abcellera Biologics apgrozījums ir 42,32 milj. USD.

gaidāmā Abcellera Biologics peļņa ir -169,96 milj. USD.

Abcellera Biologics Inc is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. The company was founded in 2012 and is headquartered in Vancouver, Canada. Abcellera works with leading pharmaceutical and biotechnology companies to accelerate the discovery and development of antibodies for the treatment of diseases such as cancer, autoimmune diseases, and infectious diseases. The company's business model is based on various areas, including the discovery and development of therapeutic antibodies, intellectual property licensing, and partnerships with other biotech companies. Abcellera's focus is on the discovery and development of antibodies with high efficacy and low side effects in the treatment of diseases. The company's product range includes bioinformatics tools, high-throughput antibody screening platforms, and an advanced antibody pipeline. The company is developing innovative technologies for the rapid discovery and development of antibodies for the treatment of specific diseases such as COVID-19 and the identification of potential drug candidates. Abcellera has a unique antibody discovery technology platform that enables the identification and validation of thousands of antibodies in a short period of time. The unmanned monitoring system of the technology platform collects data from various experiments and analyzes it to find the best antibody candidates. This approach allows potential candidates to be identified and validated faster than with conventional technologies. Abcellera also has partnerships and licensing agreements with other biotech companies. Through this collaboration, the company can provide its technologies and expertise in antibody discovery and development to jointly develop potential new drugs. The company has also made agreements with government agencies to combat COVID-19. The company operates in a highly competitive market and strives to differentiate itself from competition by gaining significance through innovation and technology development. Abcellera has made a number of strategic partnerships and investments in its technology and research to strengthen its position in the market. In summary, Abcellera's business model is focused on accelerating the discovery and development of therapeutic antibodies. The company has a unique technology platform and strategic partnerships that enable it to provide innovative solutions for a variety of medical indications. Abcellera is one of the leading companies in the industry and is expected to continue to have a high demand for its technologies and discoveries.

Abcellera Biologics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Abcellera Biologics vai uzņēmums nedod dividendes.

Abcellera Biologics ISIN ir CA00288U1066.

Abcellera Biologics WKN ir A2QKXS.

Abcellera Biologics simbols ir ABCL.

Pēdējo 12 mēnešu laikā Abcellera Biologics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Abcellera Biologics plāno maksāt dividendes 0 USD apmērā.

Abcellera Biologics pašreizējā dividendu rentabilitāte ir .

Abcellera Biologics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Abcellera Biologics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Abcellera Biologics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Abcellera Biologics apmērā 0 USD, kas tika izmaksāta 7.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.07.2024..

Pēdējās dividendes izmaksa notika 7.07.2024..

Gadā 2023, Abcellera Biologics izmaksāja 0 USD dividendes.

Abcellera Biologics dividendes tiek izmaksātas USD.